Galapagos (XTRA:GXE) - Stock Price, News & Analysis

GXE Stock Overview

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

About the company

GXE fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of 2.4% per year for the next 3 years

Shares are highly illiquid

Large one-off items impacting financial results

Galapagos NV Competitors

MorphoSys

XTRA:MOR

€2.5b

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€818.5m

Heidelberg Pharma

XTRA:HPHA

€140.3m

Price History & Performance

Summary of all time highs, changes and price drops for Galapagos
Historical stock prices
Current Share Price	€44.47
52 Week High	€66.40
52 Week Low	€42.87
Beta	0.080
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-23.98%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	382.84%

Recent updates

Shareholder Returns

	GXE	DE Biotechs	DE Market
7D	0%	1.8%	-0.3%
1Y	-24.0%	-19.9%	2.8%

Return vs Industry: GXE matched the German Biotechs industry which returned -23.4% over the past year.

Return vs Market: GXE underperformed the German Market which returned 4.7% over the past year.

Price Volatility

Is GXE's price volatile compared to industry and market?
GXE volatility
GXE Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: GXE has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GXE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	1,357	Paul Stoffels	www.glpg.com

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Galapagos NV Fundamentals Summary

How do Galapagos's earnings and revenue compare to its market cap?
GXE fundamental statistics
Market cap	€2.66b
Earnings (TTM)	€5.57m
Revenue (TTM)	€577.15m

477.7x

P/E Ratio

4.6x

P/S Ratio

Is GXE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GXE income statement (TTM)
Revenue	€577.15m
Cost of Revenue	€459.96m
Gross Profit	€117.19m
Other Expenses	€111.62m
Earnings	€5.57m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 23, 2023

Earnings per share (EPS)	0.085
Gross Margin	20.30%
Net Profit Margin	0.96%
Debt/Equity Ratio	0%

How did GXE perform over the long term?

See historical performance and comparison

GXE Stock Overview

Rewards

Risk Analysis

Galapagos NV Competitors

XTRA:MOR

€2.5b

XTRA:BIO3

€1.4b

XTRA:FYB

€818.5m

XTRA:HPHA

€140.3m

Price History & Performance

Recent News & Updates

Galapagos NV Announces Board Changes

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Recent updates

Galapagos NV Announces Board Changes

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €77.00

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

New 90-day low: €97.82

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million.

Galapagos NV Announces Dosing of the First Psoriasis Patient in the Phase 1B Trial with GLPG3667

Third quarter 2020 earnings released: €1.26 loss per share

Revenue misses expectations